PharVision Advisers’s Ambarella AMBA Stock Holding History

PharVision Advisers’s Portfolio AMBA Stock Details AMBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,153	Closed	-$343K	–	684
2025 Q3	$343K	Buy	+4,153	New	+$302K	0.19%	149
2025 Q2	–	Sell	-5,335	Closed	-$269K	–	272
2025 Q1	$269K	Buy	+5,335	New	+$365K	0.37%	117

Other funds holding AMBA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JCAM

Jericho Capital Asset Management New York $6.76B AUM 88.1% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

PharVision Advisers's AMBA Position: Q4 2025 in Review

PharVision Advisers sold out of Ambarella (AMBA) in Q4 2025, closing a stake of 4,153 shares — an estimated $343K sold.

PharVision Advisers first reported a position in AMBA in Q1 2025 and held it in 2 quarters. The position peaked at $343K in Q3 2025. 323 funds tracked by Wall St. Rank hold AMBA as of Q4 2025.

PharVision Advisers reported no remaining Ambarella position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 4,153 Ambarella shares in Q4 2025, an estimated $343K.
PharVision Advisers first reported a position in Ambarella in Q1 2025 and held it in 2 quarters.
PharVision Advisers's Ambarella position peaked at $343K in Q3 2025.
323 funds tracked by Wall St. Rank held Ambarella as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.